The cancer vaccine roller coaster
- 1 February 2009
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 27 (2), 129-139
- https://doi.org/10.1038/nbt0209-129
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Trouble at the officeNature Biotechnology, 2008
- An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trialThe Lancet, 2008
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study GroupJournal of Clinical Oncology, 2008
- Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic interventionSeminars in Cancer Biology, 2006
- Clinical Results of Vaccine Therapy for Cancer: Learning from History for Improving the FutureAdvances in Cancer Research, 2006
- Dendritic cell-based treatment of cancer: closing in on a cellular therapy.2002
- Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic CellsJournal of Clinical Oncology, 2000